论文部分内容阅读
目的探讨阿托伐他汀对糖尿病心肌病患者的左心室射血分数(LVEF)和炎症介质C-反应蛋白(CRP)的影响。方法将48例糖尿病心肌病患者随机分为对照组(24例)和治疗组(24例),两组治疗过程中均严格控制空腹血糖和餐后血糖,对照组常规予以利尿剂、血管紧张素转化酶抑制剂(ACEI)或血管紧张素Ⅱ受体拮抗剂(ARB)、洋地黄及硝酸酯类药物治疗;治疗组在对照组基础治疗上加用阿托伐他汀(20mg/d)治疗。治疗前及治疗8周后所有入选者均测LVEF及血浆CRP,观察治疗前后LVEF、CRP水平的变化。结果8周后两组患者CRP均显著下降(P<0.01);治疗组与对照组治疗后比较,P<0.05;LVEF均显著升高,对照组P<0.05,治疗组P<0.01,治疗组与对照组治疗后比较,P<0.05。结论阿托伐他汀能有效改善糖尿病心肌病患者的心功能,降低体内炎症介质水平。
Objective To investigate the effects of atorvastatin on left ventricular ejection fraction (LVEF) and inflammatory mediator C-reactive protein (CRP) in patients with diabetic cardiomyopathy. Methods 48 cases of diabetic cardiomyopathy were randomly divided into control group (24 cases) and treatment group (24 cases). Fasting blood glucose and postprandial blood glucose were both controlled in the two groups. Diuretics and angiotensin ACEI or ARB, digitalis and nitrate drugs. The treatment group was treated with atorvastatin (20mg / d) on the basis of the control group. Before treatment and after 8 weeks of treatment, all the participants were tested for LVEF and plasma CRP. The changes of LVEF and CRP before and after treatment were observed. Results After 8 weeks, CRP in both groups were significantly decreased (P <0.01); compared with the control group after treatment, P <0.05; LVEF were significantly increased in the control group P <0.05, the treatment group P <0.01, the treatment group Compared with the control group after treatment, P <0.05. Conclusion Atorvastatin can effectively improve cardiac function in patients with diabetic cardiomyopathy and reduce the level of inflammatory mediators in vivo.